Cargando…

Detection of Circulating Tumor Cells in Resectable Pancreatic Ductal Adenocarcinoma: A Prospective Evaluation as a Prognostic Marker

Circulating tumor cells (CTCs) are useful biomarkers of many solid tumors, but are infrequently detected in early stage pancreatic ductal adenocarcinomas (PDACs). The first drainage of pancreatic venous blood flow come to portal vein and pass through the liver, and they finally go out for peripheral...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Byeong Geun, Kwon, Wooil, Kim, Hyemin, Lee, Eun Mi, Han, Young Min, Kim, Hongbeom, Byun, Yoonhyeong, Lee, Kyung Bun, Lee, Kwang Hyuck, Lee, Kyu Taek, Lee, Jong Kyun, Jang, Jin-Young, Park, Joo Kyung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7930477/
https://www.ncbi.nlm.nih.gov/pubmed/33680936
http://dx.doi.org/10.3389/fonc.2020.616440
_version_ 1783660108141559808
author Song, Byeong Geun
Kwon, Wooil
Kim, Hyemin
Lee, Eun Mi
Han, Young Min
Kim, Hongbeom
Byun, Yoonhyeong
Lee, Kyung Bun
Lee, Kwang Hyuck
Lee, Kyu Taek
Lee, Jong Kyun
Jang, Jin-Young
Park, Joo Kyung
author_facet Song, Byeong Geun
Kwon, Wooil
Kim, Hyemin
Lee, Eun Mi
Han, Young Min
Kim, Hongbeom
Byun, Yoonhyeong
Lee, Kyung Bun
Lee, Kwang Hyuck
Lee, Kyu Taek
Lee, Jong Kyun
Jang, Jin-Young
Park, Joo Kyung
author_sort Song, Byeong Geun
collection PubMed
description Circulating tumor cells (CTCs) are useful biomarkers of many solid tumors, but are infrequently detected in early stage pancreatic ductal adenocarcinomas (PDACs). The first drainage of pancreatic venous blood flow come to portal vein and pass through the liver, and they finally go out for peripheral blood. We thought that comparing CTCs from portal vein and peripheral blood could enable us to understand the clinical meaning of CTCs from each different site in PDACs. Therefore, we aimed to determine 1) whether CTCs could be reliably identified in early stages (operable) of PDACs, 2) if there are any differences in the detected number of CTC in portal vein blood and peripheral blood, and 3) whether CTCs can be sensitive biomarkers for the prognosis of resectable PDAC patients. Newly diagnosed PDAC patients who underwent operation with curative intention between 2013 and 2015 were prospectively enrolled. Blood draws from portal and peripheral vein ran through the microfabricated porous filter, and anti-epithelial cell adhesion molecule (EpCAM) and anti-Plectin-1 antibodies were used for CTC identification. Baseline clinical characteristics, tumor characteristics, treatment, and clinical outcomes were assessed. The clinical stages of the 32 enrolled patients were as follows: IA/IB 1 (3.1%); IIA 9 (28.1%); IIB 17 (53.1%); III 5 (15.6%). Twenty-seven patients (84.4%) received R0 resection, while five patients (15.6%) received R1 resection. EpCAM+ CTCs were detected in 20 portal blood (62.5%) and 22 peripheral blood (68.8%). Plectin-1+ CTCs were identified in 14 portal blood (43.8%) and 16 peripheral blood (50%). Plectin-1-expressing CTCs were picked from CTC platform (microfabricated porous filter) and we could find out all KRAS mutation. Patients with detectable EpCAM+ CTC less than one in peripheral blood showed longer overall survival (OS) compared to patients with detectable CTCs more than one (35.5 months vs. 16.0 months). EpCAM and Plectin-1 successfully identified CTCs at the early stage of PDACs. Also, the number of CTCs could be a prognostic marker for survival in resectable PDACs.
format Online
Article
Text
id pubmed-7930477
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-79304772021-03-05 Detection of Circulating Tumor Cells in Resectable Pancreatic Ductal Adenocarcinoma: A Prospective Evaluation as a Prognostic Marker Song, Byeong Geun Kwon, Wooil Kim, Hyemin Lee, Eun Mi Han, Young Min Kim, Hongbeom Byun, Yoonhyeong Lee, Kyung Bun Lee, Kwang Hyuck Lee, Kyu Taek Lee, Jong Kyun Jang, Jin-Young Park, Joo Kyung Front Oncol Oncology Circulating tumor cells (CTCs) are useful biomarkers of many solid tumors, but are infrequently detected in early stage pancreatic ductal adenocarcinomas (PDACs). The first drainage of pancreatic venous blood flow come to portal vein and pass through the liver, and they finally go out for peripheral blood. We thought that comparing CTCs from portal vein and peripheral blood could enable us to understand the clinical meaning of CTCs from each different site in PDACs. Therefore, we aimed to determine 1) whether CTCs could be reliably identified in early stages (operable) of PDACs, 2) if there are any differences in the detected number of CTC in portal vein blood and peripheral blood, and 3) whether CTCs can be sensitive biomarkers for the prognosis of resectable PDAC patients. Newly diagnosed PDAC patients who underwent operation with curative intention between 2013 and 2015 were prospectively enrolled. Blood draws from portal and peripheral vein ran through the microfabricated porous filter, and anti-epithelial cell adhesion molecule (EpCAM) and anti-Plectin-1 antibodies were used for CTC identification. Baseline clinical characteristics, tumor characteristics, treatment, and clinical outcomes were assessed. The clinical stages of the 32 enrolled patients were as follows: IA/IB 1 (3.1%); IIA 9 (28.1%); IIB 17 (53.1%); III 5 (15.6%). Twenty-seven patients (84.4%) received R0 resection, while five patients (15.6%) received R1 resection. EpCAM+ CTCs were detected in 20 portal blood (62.5%) and 22 peripheral blood (68.8%). Plectin-1+ CTCs were identified in 14 portal blood (43.8%) and 16 peripheral blood (50%). Plectin-1-expressing CTCs were picked from CTC platform (microfabricated porous filter) and we could find out all KRAS mutation. Patients with detectable EpCAM+ CTC less than one in peripheral blood showed longer overall survival (OS) compared to patients with detectable CTCs more than one (35.5 months vs. 16.0 months). EpCAM and Plectin-1 successfully identified CTCs at the early stage of PDACs. Also, the number of CTCs could be a prognostic marker for survival in resectable PDACs. Frontiers Media S.A. 2021-02-18 /pmc/articles/PMC7930477/ /pubmed/33680936 http://dx.doi.org/10.3389/fonc.2020.616440 Text en Copyright © 2021 Song, Kwon, Kim, Lee, Han, Kim, Byun, Lee, Lee, Lee, Lee, Jang and Park http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Song, Byeong Geun
Kwon, Wooil
Kim, Hyemin
Lee, Eun Mi
Han, Young Min
Kim, Hongbeom
Byun, Yoonhyeong
Lee, Kyung Bun
Lee, Kwang Hyuck
Lee, Kyu Taek
Lee, Jong Kyun
Jang, Jin-Young
Park, Joo Kyung
Detection of Circulating Tumor Cells in Resectable Pancreatic Ductal Adenocarcinoma: A Prospective Evaluation as a Prognostic Marker
title Detection of Circulating Tumor Cells in Resectable Pancreatic Ductal Adenocarcinoma: A Prospective Evaluation as a Prognostic Marker
title_full Detection of Circulating Tumor Cells in Resectable Pancreatic Ductal Adenocarcinoma: A Prospective Evaluation as a Prognostic Marker
title_fullStr Detection of Circulating Tumor Cells in Resectable Pancreatic Ductal Adenocarcinoma: A Prospective Evaluation as a Prognostic Marker
title_full_unstemmed Detection of Circulating Tumor Cells in Resectable Pancreatic Ductal Adenocarcinoma: A Prospective Evaluation as a Prognostic Marker
title_short Detection of Circulating Tumor Cells in Resectable Pancreatic Ductal Adenocarcinoma: A Prospective Evaluation as a Prognostic Marker
title_sort detection of circulating tumor cells in resectable pancreatic ductal adenocarcinoma: a prospective evaluation as a prognostic marker
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7930477/
https://www.ncbi.nlm.nih.gov/pubmed/33680936
http://dx.doi.org/10.3389/fonc.2020.616440
work_keys_str_mv AT songbyeonggeun detectionofcirculatingtumorcellsinresectablepancreaticductaladenocarcinomaaprospectiveevaluationasaprognosticmarker
AT kwonwooil detectionofcirculatingtumorcellsinresectablepancreaticductaladenocarcinomaaprospectiveevaluationasaprognosticmarker
AT kimhyemin detectionofcirculatingtumorcellsinresectablepancreaticductaladenocarcinomaaprospectiveevaluationasaprognosticmarker
AT leeeunmi detectionofcirculatingtumorcellsinresectablepancreaticductaladenocarcinomaaprospectiveevaluationasaprognosticmarker
AT hanyoungmin detectionofcirculatingtumorcellsinresectablepancreaticductaladenocarcinomaaprospectiveevaluationasaprognosticmarker
AT kimhongbeom detectionofcirculatingtumorcellsinresectablepancreaticductaladenocarcinomaaprospectiveevaluationasaprognosticmarker
AT byunyoonhyeong detectionofcirculatingtumorcellsinresectablepancreaticductaladenocarcinomaaprospectiveevaluationasaprognosticmarker
AT leekyungbun detectionofcirculatingtumorcellsinresectablepancreaticductaladenocarcinomaaprospectiveevaluationasaprognosticmarker
AT leekwanghyuck detectionofcirculatingtumorcellsinresectablepancreaticductaladenocarcinomaaprospectiveevaluationasaprognosticmarker
AT leekyutaek detectionofcirculatingtumorcellsinresectablepancreaticductaladenocarcinomaaprospectiveevaluationasaprognosticmarker
AT leejongkyun detectionofcirculatingtumorcellsinresectablepancreaticductaladenocarcinomaaprospectiveevaluationasaprognosticmarker
AT jangjinyoung detectionofcirculatingtumorcellsinresectablepancreaticductaladenocarcinomaaprospectiveevaluationasaprognosticmarker
AT parkjookyung detectionofcirculatingtumorcellsinresectablepancreaticductaladenocarcinomaaprospectiveevaluationasaprognosticmarker